Supplemental material for "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)"

Published: 20 September 2019| Version 1 | DOI: 10.17632/fj89yr8c9s.1
Contributor:
Mark Lebwohl

Description

Supplemental material for Lebwohl et al, "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)," JAAD, 2019.

Files